decemb
transmiss
zair
ebolaviru
ebola
viru
ebov
human
occur
southeastern
guinea
spread
liberia
sierra
leon
rapidli
surpass
cumul
total
previou
ebola
viru
diseas
evd
outbreak
prior
outbreak
occur
primarili
remot
resourcechalleng
set
case
fatal
proport
current
outbreak
due
size
spread
west
africa
addit
export
medic
evacu
case
europ
north
america
engag
much
broader
health
worker
commun
includ
critic
care
clinician
clinic
manifest
durat
ill
transmiss
appear
similar
previou
evd
outbreak
avail
provis
advanc
support
care
europ
north
america
mortal
less
emphas
potenti
import
support
critic
care
manag
evd
patient
review
provid
uptod
examin
evd
use
knowledg
gain
west
african
outbreak
highlight
relev
critic
care
physician
viral
hemorrhag
fever
describ
syndrom
acut
sever
febril
ill
caus
virus
four
differ
taxonom
arenavirida
bunyavirida
flavivirida
although
differ
diseas
epidemiolog
transmiss
pathogenesi
rna
virus
zoonot
caus
nonspecif
symptom
includ
fever
headach
weak
vomit
diarrhea
infect
filovirus
includ
marburg
ebola
virus
associ
rapid
progress
hemodynam
instabl
shock
multiorgan
dysfunct
filovirus
discov
laboratori
worker
becam
ill
come
contact
green
monkey
import
africa
newli
discov
viru
kill
infect
worker
german
town
marburg
ebola
viru
discov
simultan
outbreak
zair
sudan
patient
die
respect
sinc
discoveri
approxim
evd
outbreak
west
african
evd
outbreak
first
recogn
march
forest
region
southeastern
guinea
howev
first
evd
case
may
happen
earli
decemb
zoonot
transmiss
ebov
anim
human
subsequ
humantohuman
spread
transmiss
like
well
underway
throughout
west
africa
spring
june
hundr
confirm
probabl
evd
case
end
abil
provid
exist
ebola
treatment
unit
isol
care
eventu
case
end
decemb
may
report
confirm
probabl
suspect
evd
case
death
guinea
sierra
leon
liberia
anoth
case
primarili
receiv
care
mali
seneg
nigeria
well
countri
outsid
africa
includ
usa
uk
germani
spain
franc
itali
netherland
norway
switzerland
tabl
addit
file
evd
case
west
africa
report
equal
among
male
femal
children
year
age
account
young
adult
year
older
adult
year
report
case
persontoperson
transmiss
ebov
occur
mucou
membran
contact
bodili
fluid
eg
vomit
fece
blood
infect
symptomat
touch
bodi
someon
die
evd
droplet
transmiss
less
like
occur
due
low
preval
respiratori
symptom
anim
transmiss
model
aerosol
ebov
clinic
relev
small
particl
droplet
nuclei
transmiss
unclear
may
appli
care
critic
ill
patient
undergo
aerosolgener
procedur
intub
ventil
bronchoscopi
percutan
transmiss
sharp
needlestick
glassrel
exposur
contamin
infect
bodili
fluid
thought
effici
mechan
ebola
viru
transmiss
concern
ebov
transmiss
posit
infect
prevent
control
ipc
center
clinic
care
theoret
meticul
provis
contact
precaut
hand
wash
use
glove
gown
along
protect
mucu
membran
eye
nose
mouth
exposur
proper
don
dof
person
protect
equip
ppe
suffici
prevent
nosocomi
ebov
transmiss
nonclimatecontrol
west
african
ebola
treatment
facil
fig
heat
humid
prevent
optim
function
medic
mask
duckbil
respir
humid
sweat
caus
sag
collaps
tight
fit
goggl
often
fog
reduc
visibl
face
shield
afford
improv
visibl
must
provid
suffici
coverag
without
risk
splashrel
facial
exposur
halfspher
semirigid
respir
tend
resist
moisturerel
collaps
deform
howev
concern
high
mortal
evd
led
ipc
ppe
choic
field
sometim
follow
tradit
infect
control
recommend
guidanc
intern
technic
organ
often
result
ppe
safe
toler
healthcar
personnel
min
due
excess
heat
humid
risk
syncop
potenti
danger
behaviour
eg
adjust
fog
facial
protect
soil
glove
inabl
safe
perform
task
insert
intraven
cathet
west
africa
ebola
viru
transmiss
like
also
occur
among
healthcar
personnel
inform
healthcar
provis
commun
patient
colleagu
without
appropri
infect
prevent
control
practic
nosocomi
ebov
transmiss
spain
usa
similarli
reinforc
import
rigor
ebola
ipc
practic
healthcar
personnel
train
irrespect
healthcar
system
pathogenesi
evd
human
remain
poorli
understood
show
similar
differ
caus
viral
hemorrhag
fever
bacteri
sepsi
endorgan
dysfunct
seem
result
combin
direct
viral
cytopath
effect
host
immun
respons
underresuscit
hypovolem
shock
ebov
bind
lectin
surfac
receptor
monocyt
macrophag
dendrit
cell
target
viruscontain
cell
spread
lymphat
system
liver
spleen
result
wide
dissemin
viral
infect
endotheli
cell
infect
activ
may
lead
increas
level
solubl
adhes
molecul
thombomodulin
inflammatori
mediat
interferongamma
alpha
interleukin
il
interferoninduc
protein
tumor
necrosi
factor
alpha
result
vascular
injuri
thrombocytopenia
consumpt
reduc
product
clot
factor
addit
increas
concentr
fibrin
degrad
product
patient
sever
evd
may
contribut
bleed
hepatocellular
inflamm
common
myositi
elev
creatin
kinas
pancreat
elev
blood
amylas
lipas
level
occur
sever
case
acut
kidney
injuri
often
explain
underresuscit
hypovolemia
might
also
aris
viral
secondari
bacteri
sepsi
acut
tubular
necrosi
myoglobinuria
microvascular
renal
thrombi
associ
sepsi
dissemin
intravascular
coagul
adren
gland
viral
infect
shown
anim
model
might
contribut
hypotens
renal
sodium
loss
hypovolemia
diagnost
test
recommend
patient
exhibit
symptom
meet
evd
case
definit
ebola
viral
rna
detect
clinic
specimen
realtim
revers
transcript
polymeras
chain
reaction
rtpcr
viru
detect
specif
antigen
diagnost
test
detect
igm
antibodi
direct
ebov
rtpcr
use
confirm
sensit
molecular
test
depend
ebola
viral
load
specimen
collect
within
day
symptom
onset
may
fals
neg
due
undetect
viremia
earli
clinic
cours
circumst
anoth
blood
specimen
rtpcr
test
collect
day
symptom
onset
pointofcar
rapid
diagnost
test
rdt
test
field
lack
sensit
requir
cold
chain
remain
evalu
clinic
trial
cumul
case
fatal
proport
west
africa
approxim
may
vari
substanti
cours
outbreak
higher
near
begin
comparison
cumul
case
fatal
proport
patient
treat
western
europ
usa
tabl
case
fatal
remain
highest
among
young
children
older
adult
pregnant
women
often
experi
spontan
abort
follow
bleed
well
preterm
labor
stillbirth
ebola
viru
infect
occur
later
pregnanc
vertic
transmiss
subsequ
neonat
mortal
virtual
uniform
document
live
birth
women
acut
evd
high
ebola
viral
load
time
admiss
associ
sever
ill
mortal
marker
organ
dysfunct
variabl
associ
outcom
manag
critic
ill
evd
patient
resourceconstrain
set
histor
restrict
variabl
monitor
daili
clinic
sign
symptom
without
access
continu
assess
need
strict
ipc
practic
separ
patient
care
area
west
africa
significantli
limit
document
review
daili
clinic
record
insid
outsid
highrisk
patient
care
case
burden
decreas
ratio
healthcar
personnel
patient
increas
assess
perform
systemat
ebola
treatment
facil
temperatur
heart
rate
blood
pressur
respiratori
rate
puls
oximetri
qualit
descript
urin
gastrointestin
output
well
fluid
balanc
estim
laboratori
data
ebola
rtpcr
result
essenti
unavail
ebola
treatment
facil
west
africa
earli
outbreak
initi
limit
attent
diagnost
ebola
rtpcr
pointofcar
system
monitor
biochemistri
hematolog
paramet
piccolo
inconsist
util
insid
ebola
treatment
facil
part
due
limit
manufacturerrecommend
temperatur
humid
rang
cours
west
african
outbreak
support
nation
deploy
intern
laboratori
basic
biochemistri
blood
count
coagul
profil
help
character
cours
ill
remain
inconsist
avail
often
substanti
delay
result
report
due
transport
process
time
malaria
rapid
diagnost
test
less
commonli
rtpcr
avail
laboratori
support
ebola
treatment
facil
west
africa
howev
test
lassa
fever
viru
endem
ebovaffect
countri
caus
sepsi
routin
bedsid
ultrasonographi
wide
deploy
could
help
assess
volum
statu
respons
intraven
fluid
assess
challeng
clinic
sign
abdomin
distens
plain
chest
abdomen
radiographi
perform
european
north
american
set
rare
avail
patient
ebola
west
africa
among
patient
treat
usa
europ
pulmonari
edema
report
acut
respiratori
distress
syndrom
anoth
world
health
organ
recommend
consid
discharg
patient
isol
basi
neg
blood
ebola
viru
rtpcr
result
taken
least
day
resolut
symptom
howev
ebola
viru
persist
certain
bodi
fluid
undetect
blood
clinic
recoveri
evd
viabl
ebola
viru
isol
urin
semen
cerebrospin
fluid
vitreou
humor
mani
month
blood
clearanc
suggest
activ
unprotect
sex
invas
procedur
penetr
eye
trauma
confer
transmiss
risk
even
symptom
viremia
resolv
therefor
critic
counsel
evd
survivor
risk
ebola
viru
persist
appropri
precaut
discharg
includ
barrier
protect
sexual
intercours
semen
test
neg
ebola
viru
twice
least
month
evd
onset
health
worker
other
continu
appli
standard
precaut
patient
evalu
evd
survivor
convalesc
period
addit
infect
prevent
control
practic
base
upon
individu
patient
risk
assess
may
prudent
specif
procedur
convalesc
even
detect
ebov
blood
eg
lumbar
punctur
vitreou
humor
sampl
provid
support
care
critic
ill
patient
evd
resourcepoor
set
challeng
due
limit
infrastructur
lack
materi
train
healthcar
personnel
uncertainti
regard
translat
modern
sepsi
treatment
strategi
optim
intraven
fluid
manag
protocol
absenc
advanc
monitor
use
resourcerich
set
respiratori
symptom
cough
promin
featur
evd
tachypnea
like
repres
respiratori
compens
sever
metabol
acidosi
translat
fluid
resuscit
protocol
use
resourcerich
set
set
supplement
oxygen
therapi
routin
avail
diseas
possibl
vascular
leak
syndrom
could
result
increas
morbid
warrant
investig
use
antibiot
common
ebola
treatment
facil
diagnosi
evd
confirm
febril
patient
empir
treatment
potenti
bacteri
coinfect
gastrointestin
bacteri
transloc
patient
confirm
evd
howev
disrupt
gastrointestin
flora
due
broadspectrum
antibiot
could
exacerb
diarrhea
fluid
loss
symptomat
treatment
sever
diarrhea
loperamid
variabl
employ
across
ebola
treatment
facil
risk
benefit
practic
warrant
evalu
observ
studi
clinic
trial
earli
peak
outbreak
clinic
manag
gener
limit
support
care
focus
aggress
oral
occasion
intraven
volum
resuscit
case
number
decreas
advanc
care
becam
common
treatment
facil
despit
limit
work
ppe
feasibl
safeti
central
venou
cathet
placement
demonstr
uk
militarysupport
treatment
facil
kerri
town
sierra
leon
feasibl
transthorac
echocardiographi
demonstr
militari
ebola
treatment
facil
conakri
guinea
middecemb
emerg
italian
nongovernment
organ
establish
ebola
critic
care
unit
lakka
goderich
sierra
leon
latter
consist
constant
bedsid
nurs
continu
blood
pressur
heart
rate
respiratori
rate
monitor
puls
oximetri
arteri
venou
cannul
nasogastr
tube
feed
invas
ventil
continu
renal
replac
therapi
diagnost
biochemistri
hematolog
ultrasonographi
plain
radiographi
fig
wane
case
number
accur
evalu
impact
intervent
patient
outcom
possibl
site
goalsupport
mathaska
ebola
treatment
unit
etu
partner
healthsupport
maforki
etu
sierra
leona
also
began
use
aspect
critic
care
procedur
februari
includ
nasogastr
tube
feed
bedsid
ultrasound
well
intraosseu
cannul
intraven
fluid
resuscit
histor
philosophi
provid
oral
fluid
evd
care
given
way
deliveri
contextappropri
critic
care
date
patient
manag
nine
countri
outsid
west
africa
tabl
describ
surviv
tabl
thirteen
detail
account
evd
manag
modern
healthcar
set
usa
germani
spain
switzerland
provid
insight
cours
ill
tabl
case
report
confirm
intens
care
monitor
appropri
prepar
center
feasibl
noninvas
ventil
mechan
ventil
central
venou
cathet
insert
vasopressor
support
renal
replac
therapi
provid
effect
safe
tabl
fig
current
evd
treatment
focus
support
care
specif
treatment
option
yet
proven
effect
number
ebolaspecif
treatment
strategi
undergon
preliminari
clinic
trial
investig
includ
convalesc
plasma
favipiravir
brincidofovir
transfus
convalesc
whole
blood
plasma
donat
evd
survivor
use
prior
evd
outbreak
uncontrol
compassionateus
basi
anim
model
one
three
clinic
trial
convalesc
plasma
therapi
complet
report
nonrandom
comparison
histor
control
transfus
ml
convalesc
plasma
unknown
level
neutral
antibodi
patient
confirm
evd
associ
signific
improv
surviv
seriou
advers
reaction
trial
transfusionrel
acut
lung
injuri
describ
convalesc
plasma
therapi
spain
favipiravir
toyama
japan
preexist
influenza
viru
inhibitor
administ
compassion
use
outsid
west
africa
multicent
nonrandom
clinic
trial
guinea
patient
receiv
favipiravir
similar
surviv
base
upon
histor
control
patient
trial
author
suggest
favipiravir
studi
patient
medium
high
viremia
high
viremia
brincidofovir
chimerix
usa
nucleotid
analog
inhibit
rnapolymeras
vitro
activ
ebola
administ
small
number
evd
patient
uncontrol
compassion
use
test
phase
clinic
trial
liberia
stop
manufactur
withdrew
studi
support
formul
lipidnanoparticleencapsul
small
interf
ribonucl
acid
sirna
target
two
protein
involv
ebola
viru
transcript
replic
tekmira
usa
canada
use
nonhuman
primat
ebola
viru
infect
postexposur
treatment
strategi
patient
medic
evacu
west
africa
uncontrol
compassion
use
howev
phase
clinic
trial
rapidetkm
sierra
leon
halt
accord
preestablish
stop
rule
zmapp
monoclon
antibodi
cocktail
leafbio
usa
use
emerg
investig
new
drug
approv
food
drug
administr
patient
treat
usa
west
africa
western
europ
zmapp
treatment
rhesu
macaqu
result
surviv
even
start
day
lethal
ebov
infect
random
control
trial
investig
therapeut
evd
zmapp
plu
standard
care
compar
standard
care
alon
evd
patient
four
countri
includ
three
impact
west
african
countri
due
declin
evd
case
unblind
zmapp
random
control
trial
enrol
prespecifi
target
goal
evd
patient
data
analyz
evd
patient
mortal
zmapp
treatment
group
versu
untreat
group
differ
statist
signific
openlabel
uncontrol
select
administr
agent
amiodaron
hmgcoa
reductas
inhibitor
angiotensin
ii
receptor
antagonist
therapi
counteract
vascular
leak
preclud
conclus
observ
studi
examin
tempor
trend
mortal
among
patient
evd
one
etu
guinea
patient
receiv
malaria
prophylaxi
die
compar
patient
receiv
adjust
analys
risk
ratio
confid
interv
stronger
effect
observ
among
patient
without
malaria
find
confirm
random
clinic
trial
two
vaccin
candid
demonstr
efficaci
nonhuman
primat
recombin
replicationcompet
vesicular
stomat
virusbas
vaccin
express
surfac
glycoprotein
zair
ebolaviru
rvsv
evalu
openlabel
ring
vaccin
trial
involv
peopl
cluster
random
immedi
delay
day
administr
vaccin
well
toler
immedi
vaccin
group
new
evd
case
delay
vaccin
group
evd
case
anoth
candid
vaccin
remain
investig
vaccin
candid
also
develop
evalu
sever
healthcar
personnel
receiv
postexposur
prophylaxi
differ
intervent
includ
candid
ebola
vaccin
follow
potenti
highrisk
exposur
ebola
viru
although
ebola
viru
diseas
occur
individu
conclus
made
effect
uncontrol
intervent
commonli
appli
four
principl
medic
bioethic
face
numer
threat
treat
patient
evd
symptomat
patient
autonomi
seek
treatment
isol
weigh
threat
diseas
transmiss
stay
commun
injustic
treatment
variabl
across
region
time
place
patient
differenti
risk
death
act
benefic
healthcar
worker
inher
place
risk
natur
respons
balanc
risk
duti
help
frequent
conspir
greater
number
health
worker
respond
ebola
outbreak
duti
nonmalefic
harm
daili
conundrum
potenti
delay
routin
diagnost
workup
common
ill
lack
diagnost
test
resourceconstrain
environ
inadequ
space
separ
potenti
infecti
suspect
patient
along
gradient
risk
evd
survivor
increas
recognit
postebola
syndrom
convalesc
period
character
mental
health
cognit
sequela
chronic
headach
insomnia
arthralgia
auditori
disturb
ocular
effect
includ
sightthreaten
uveiti
uncertain
whether
manifest
due
direct
viral
cytopath
effect
immuneprivileg
compart
postinfecti
immunemedi
inflamm
although
evd
outbreak
narrow
knowledg
gap
pathophysiolog
immunolog
respons
acut
infect
convalesc
still
minim
character
access
rapid
pointofcar
evd
diagnost
capac
differenti
common
febril
ill
critic
earli
present
evd
broad
differenti
diagnosi
laboratori
test
identifi
prognost
indic
could
help
guid
clinic
care
evalu
specif
antivir
therapi
critic
evalu
commonli
use
treatment
still
limit
evid
eg
empir
antibiot
antidiarrh
agent
fluid
replac
composit
volum
safeti
function
ppe
must
improv
standard
easytous
clinic
chart
human
resourc
data
entri
made
avail
support
cohort
studi
clinic
trial
seem
intuit
provis
advanc
support
critic
care
improv
patient
outcom
operation
evalu
increas
level
care
resourcechalleng
environ
need
prepar
research
protocol
rapidli
adapt
countryspecif
set
quickli
implement
could
reduc
research
delay
futur
outbreak
follow
patient
surviv
evd
import
better
character
immun
correl
viru
clearanc
host
genet
factor
contribut
surviv
better
address
morbid
postebola
syndrom
provis
advanc
support
critic
care
evd
patient
challeng
possibl
west
african
develop
healthcar
set
creat
evalu
contextappropri
intens
care
capac
knowledg
translat
prioriti
experi
outbreak
emphas
addit
evalu
specif
medic
treatment
improv
global
capac
provid
support
critic
care
patient
sever
ill
may
associ
greatest
opportun
improv
patient
outcom
cpr
cardiopulmonari
resuscit
ebov
ebola
viru
etu
ebola
treatment
unit
evd
ebola
viru
diseas
icu
intens
care
unit
il
interleukin
ipc
infect
prevent
control
ppe
person
protect
equip
rtpcr
realtim
revers
transcript
polymeras
chain
reaction
